Accompanied by Gan Jianmin, the chairman of Minkang and general assistant Jiao Yang, the leaders visited the exhibition hall of Minkang and learned about the full range of products independently developed and produced by Minkang, covering the detection of multiple indicators such as blood glucose, blood lipids, blood ketone, uric acid, glycosylated hemoglobin, and the honors and patents. Gan Jianmin introduced the development process and corporate culture of Minkang in detail to the leaders.

Subsequently, Dr.Cai Zongzhe, the chief scientist of Minkang, focused on the research and development of Minkang CGM continuous dynamic blood glucose monitoring project. From the market prospect of CGM, to the working principle, applicable population, monitoring effect, and to the research and development progress of Minkang CGM project, Dr. Cai Zongzhe elaborated in detail and displayed the current research and development results.Finally,all leaders fully affirmed the design and R&D advantages of Minkang CGM products.

Minkang has formed the four leading technical systems of electrochemistry, photochemistry, colloidal gold and immunity in China, and has rapidly upgraded according to the development path of blood glucose detection - multi-indicator detection - intelligent detection. In 2022, Minkang will continue to build an ecological closed-loop of chronic disease management from monitoring to data analysis to the implementation of diagnosis and treatment programs,bring benefits to more patients with chronic diseases.